Abstract
Introduction: It aimed to assess the clinical outcome of transcatheter arterial chemoembolization (TACE) and its combination with microwave ablation (MWA) in middle or advanced primary liver cancer(PLC), and to analyze the causes complications. Material and Method: According to the treatment methods, 100 patients with middle or advanced PLC were divided into TACE group (TACEG) and TACE+MWA group (combination group, CG) (50 cases in each). The TACEG was treated with TACE alone, and the CG adopted TACE combined with MWA. The quality of life (QoL)SF-36 score, serum liver function index, response, 1-year overall survival (OS) rate, and complication rate were observed before and following remedy. Result: As against the TACEG, following remedy, the CG had a higher SF-36 score,objective relief rate (ORR) (32% vs 50%), disease control rate (DCR)(82% vs 90%), and 1-year OS (60% vs 84%) and a lower 1-year complication rate (34% vs 16%);Following remedy, as against the TACEG, serum cholyglycine (CG) and prealbumin (PAB) levels were higher, and the levels of total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyltranspetidase (GGT), and Alpha fetoprotein (AFP) were lower in the CG (all P<0.05). Conclusion: TACE combined with MWA is effective and safe in middle or advanced PLC, and can markedly improve liver function and postoperative survival rate(SR).
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.